Insmed INSM Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| ARIKAYCE external R&D expenses | $8.62M-28.9% | $9.1M-39.6% | $9.21M-43.7% | $11M-26.1% | $12.12M-13.0% | |
| Brensocatib external R&D expenses | $18.48M-10.5% | $22.94M-4.2% | $19.36M+12.0% | $33.56M-11.2% | $20.66M+5.9% | |
| Other external R&D expenses | $32.68M+16.4% | $36.76M+3.6% | $36.58M+35.9% | $28.45M+90.7% | $28.08M+112% | |
| TPIP external R&D expenses | $37.34M+308% | $35.65M+71.8% | $28.75M+72.9% | $20.65M+39.8% | $9.15M-33.6% | |
| Intangibles, net by Product | ||||||
| AstraZeneca milestone | $43.23M— | $44.05M— | $29.73M— | —— | —— | |
| PARI milestones | $911K— | $962K-17.4% | $1.01M— | —— | —— | |
| Intangible Amortization by Product | ||||||
| AstraZeneca milestone | $818K— | $674K— | —— | —— | —— | |
| PARI milestones | $51K— | $51K+1.0% | —— | —— | —— | |
| Additions by Product | ||||||
| AstraZeneca milestone | $0— | $15M— | —— | —— | —— | |
| PARI milestones | $0— | $0— | —— | —— | —— | |
| Product revenues, net by Geography | ||||||
| International | $35.9M+25.7% | $45.88M+25.2% | $40.31M+51.8% | $38.73M— | $28.55M— | |
| US | $270.07M+320% | $217.96M+222% | $102.04M+52.6% | $68.68M+7.7% | $64.28M+14.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insmed break its business down?
- Insmed (INSM) reports r&d by product across 5 parts — ARIKAYCE external R&D expenses, Brensocatib external R&D expenses, INS1148, Other external R&D expenses and TPIP external R&D expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Insmed's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insmed's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
